Exosomes are extracellular vesicles that play an important role in cell-to-cell communication and act as carriers of circulating nucleic acids, lipids and proteins in body. Over time, various research studies have demonstrated the potential of exosomes in disease diagnosis and drug delivery applications, owing to their ability to act as biomarkers for various diseases and transport important functional elements. Given the various benefits, exosomes have gained significant interest in the biopharmaceutical industry, likely to result in their increased demand. However, the development and manufacturing of exosomes is associated with several challenges, including lack of standardized isolation and purification methods, limited drug loading ability, and inadequate clinical grade production and GMP compliant industrial scale-up. Therefore, outsourcing of exosome development and manufacturing is seen as a preferable option by companies focused on development of exosome based diagnostics and therapeutics.
Presently, several companies offer services for exosome development and manufacturing. The primary benefit of engaging service providers is to overcome various challenges related to exosome development, such as heterogeneity of exosomes, optimization of exosome isolation, purification and characterization methods and lack of specific biomarkers. Further, in order to leverage the full potential of exosomes, advanced exosome technologies are being developed to fully substructure their therapeutic applications. In addition, extensive research is being conducted to develop methods for extraction of exosomes with high level of purity and sensitivity. The growth in research over the last few years is evident from the published scientific literature and the clinical trial activity in this domain. The market has also witnessed substantial partnership activity, including several technology licensing deals. Moreover, the service providers are actively upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for these extracellular vesicles. Driven by the ongoing research activity, technological advancements and efforts of the players offering exosome development and manufacturing services, the market is poised to witness healthy growth over the next decade.
The “Exosome Development and Manufacturing Services Market by Scale of Operation (Discovery / Research, Preclinical and Clinical) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely future potential of exosome service providers over the next decade. The study underlines an in-depth analysis, highlighting the diverse capabilities of various industry stakeholders engaged in this field.
The opinions and insights presented in the report were influenced by discussions held with several stakeholders in this domain.
Presently, several companies offer services for exosome development and manufacturing. The primary benefit of engaging service providers is to overcome various challenges related to exosome development, such as heterogeneity of exosomes, optimization of exosome isolation, purification and characterization methods and lack of specific biomarkers. Further, in order to leverage the full potential of exosomes, advanced exosome technologies are being developed to fully substructure their therapeutic applications. In addition, extensive research is being conducted to develop methods for extraction of exosomes with high level of purity and sensitivity. The growth in research over the last few years is evident from the published scientific literature and the clinical trial activity in this domain. The market has also witnessed substantial partnership activity, including several technology licensing deals. Moreover, the service providers are actively upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for these extracellular vesicles. Driven by the ongoing research activity, technological advancements and efforts of the players offering exosome development and manufacturing services, the market is poised to witness healthy growth over the next decade.
Scope of the Report
The “Exosome Development and Manufacturing Services Market by Scale of Operation (Discovery / Research, Preclinical and Clinical) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely future potential of exosome service providers over the next decade. The study underlines an in-depth analysis, highlighting the diverse capabilities of various industry stakeholders engaged in this field.
In addition to other elements, the report includes:
- A detailed assessment of the current market landscape of exosome service providers along with the information on their year of establishment, company size, location of headquarters, types of service(s) offered (isolation, characterization, purification, chromatography, engineering, targeted delivery, diagnostic biomarker, and quality control), method of isolation, method of purification, method of characterization, method of exosome manufacturing (engineering and targeted delivery), scale of operation (discovery / research, pre-clinical, clinical or commercialized) and scalability (small, mid-sized or large).
- A competitiveness analysis of exosome service providers based on various relevant parameters, such as supplier strength (based on the experience / expertise of the service providers and company size), service strength (number of stages of development (discovery, preclinical, clinical or commercialized), scalability criteria, number of isolation and purification methods, number of characterization methods, number of chromatography techniques, quality control methods and exosome manufacturing methods).
- Detailed profiles of prominent exosome service providers. Each company profile features a brief overview of the company, its financial information (if available), details on its exosome service portfolio, recent developments and an informed future outlook.
- An analysis of the partnerships that have been established in this domain since 2016, covering R&D agreements, research, development and commercialization collaborations, product development agreements, mergers and acquisitions, product development and commercialization agreements, distribution / supply agreements, licensing deals, asset acquisitions, and clinical trial agreements.
- A detailed review of 6,451 peer-reviewed, scientific articles related to research on exosomes on the basis of several relevant parameters, such as year of publication, type of service(s) offered, emerging focus areas. The chapter also highlights the top journals (in terms of number of articles published and impact factor).
- A detailed analysis of the global events attended by the participants, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participant, active speakers (in terms of number of events). The chapter also highlights the geographical mapping of upcoming events.
- An overview of the landscape of exosome-based technologies, featuring analyses of various technology providers, based on several relevant parameters, such as year of establishment, company size and location of headquarters.
- An insightful analysis of the patents filed / granted for exosome technologies, during the period between 2016 and 2021 (till November), taking into consideration several relevant parameters, such as type of patent, publication year, application year, geographical location, Cooperative Patent Classification (CPC) symbols, emerging focus areas, leading industry and non-industry players (on the basis of number of patents) and individual patent assignees (in terms of size of intellectual property portfolio), patent benchmarking, patent characteristics and age of patents. The chapter also includes an insightful valuation analysis.
- A detailed analysis of completed and ongoing clinical trials of exosomes, based on different parameters, such as trial status, trial registration year, trial registration year and enrolled patient population, trial recruitment status, trial phase and number of patients enrolled, study design, type pf sponsor / collaborator, leading players (on basis of number of registered trials),emerging focus areas and location of the trials (on basis of number of registered trials and enrolled patient population).
The opinions and insights presented in the report were influenced by discussions held with several stakeholders in this domain.
The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):
- Jonathan Carson (Strategic Marketing Manager, EVerZom)
- Navdeep Singh (Product Manager and Technical Lead, Clara Biotech)
- Nicolas Rousseau (Chief Compliance Officer and Co-founder, RoosterBio)
Key Questions Answered
- Who are the leading players offering exosome related services?
- Which are the various technology platforms available in the market for the development of exosomes?
- What is the relative competitiveness of different exosome service providers?
- What kind of partnership models are commonly adopted by industry and non-industry stakeholders?
- What is the focus area of the ongoing research activities related to exosomes?
- How has the intellectual property landscape of exosomes evolved over the years?
- What are the key agenda items being discussed in various global events / conferences related to exosomes?
- Which companies are actively involved in conducting clinical trials for exosomes?
- How is the current and future market opportunity related to exosomes, likely to be distributed across key market segments?
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
1. PREFACE
3. INTRODUCTION
4. EXOSOME SERVICE PROVIDERS: MARKET LANDSCAPE
5. COMPANY COMPETITIVENESS ANALYSIS
6. COMPANY PROFILES: EXOSOME SERVICE PROVIDERS
7. PARTNERSHIPS AND COLLABORATIONS
8. PUBLICATION ANALYSIS
9. GLOBAL EVENT ANALYSIS
10. EXOSOME BASED TECHNOLOGIES: MARKET OVERVIEW
11. PATENT ANALYSIS
12. CLINICAL TRIAL ANALYSIS
13. MARKET FORECAST
15. EXECUTIVE INSIGHTS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 101 Bio
- 10x Genomics
- Aegle Therapeutics
- Aethlon Medical
- AlfatestLab
- American Association for the Advancement of Science (AAAS)
- American Society for Bone and Mineral Research (ASBMR)
- Amgen
- AMSBIO
- Anjarium Biosciences
- Anopoli Biomedical Systems
- Aruna Bio
- ASN Events
- Beth Israel Deaconess Medical Center
- BioCat
- BioPharma Asia
- Biosyyd
- BioTech Pharma Summit
- Bio-Techne
- BioXpedia
- Broad Institute of MIT and Harvard
- Cambridge Bioscience
- Capital Biosciences
- Capricor Therapeutics
- CD Bioparticles
- Cell Guidance Systems
- Cellex
- Cellular Biomedicine Group (CBMG)
- Center for Biologics Evaluation and Research (CBER)
- CHA Biotech
- Ciloa
- Clara Biotech
- Codiak BioSciences
- Craif
- Creative Bioarray
- Creative Biolabs
- Creative Biostructure
- Creative Proteomics
- Curexsys
- David H. Murdock Research Institute (DHMRI)
- Direct Biologics
- Editas Medicine
- EriVan Bio
- European Society of Cardiology (ESC)
- Esco Aster
- EV Therapeutics
- Evercyte
- EVerZom
- Evox Therapeutics
- Excilone
- Excipio Technologies
- EXIT071
- ExoCoBio
- Exogenus Therapeutics
- Exolitus
- ExoModTech
- Exopharm
- Exosome Diagnostics
- Exosome Sciences (Acquired by Aethlon Medical)
- Exosome Plus
- Exosomics
- ExoVectory
- Finnish Red Cross
- Florica Therapeutics
- Frontage Laboratories
- Fusion Conferences
- GeneCopoeia
- George Mason University
- Goodwin Biotechnology
- HansaBioMed Life Sciences (Acquired by Lonza)
- Hanson Wade
- Harvard University
- Henry Ford Health System
- ILIAS Biologics
- Immunostep
- Innovex Therapeutics
- Inscripta
- Intezyne Technologies
- Italian Association of Cell Culture (AICC)
- Izasa Scientific
- Izon Science
- Jazz Pharmaceuticals
- Kimera Labs
- Lifeasible
- Lonza
- Luminous BioSciences
- Macrogen
- Mahe Technologies
- Mantra Bio
- Marin Biologic Laboratories
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- MDimune
- Merck
- Miltenyi Biotec
- Moderna
- Nanovex Biotechnologies
- NanoView Biosciences
- National Cancer Institute (NCI)
- National Institute for Health and Medical Research (INSERM) (Acquired by Inserm Transfert)
- National Taiwan University Hospital
- NeuroDex
- Norgen Biotek
- Novus Biologicals (Acquired by Bio-Techne)
- NurExone Biologic
- Ocean Ridge Biosciences
- Omnigene Medical technologies
- OmniSpirant
- OPTOLANE Technologies
- Organicell Regenerative Medicine
- Pathways to Stem Cell Science
- Progenity
- QIAGEN
- Quantum Design
- Ragon Institute of MGH, MIT and Harvard
- Regeneron Pharmaceuticals
- ReNeuron
- RoosterBio
- Ruijin Hospital
- Sanford Burnham Prebys Medical Discovery Institute
- Sarepta Therapeutics
- System Biosciences (SBI)
- SelectBIO
- SMi Group
- Spectradyne
- Stanford University
- Sumika Chemical Analysis Service
- System Biosciences
- Takeda
- The Cell Factory
- University Medical Center Utrecht
- University of Texas
- Thermo Fisher Scientific
- Thomas Jefferson University
- Toray Industries
- Tymora Analytical Operations
- UCL Translational Research Office
- uFluidix
- University Hospital Bonn (UKB)
- Unicyte
- University of California
- University of Paris, France
- Vanderbilt University
- Vesigen Therapeutics
- Vironova
- VivaZome Therapeutics
- Xollent Biotech
- XOStem
Methodology
LOADING...